Intellia Therapeutics Inc. (NTLA)
$12.82
$0.14
(1.06%)
As on 04-Sep-2026 13:36EDT
Market cap
$1,803 Mln
Revenue (TTM)
$60 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.4
-
Face value
--
-
Shares outstanding
140,126,693
10 Years Aggregate
CFO
$-1,201.23 Mln
EBITDA
$-1,640.01 Mln
Net Profit
$-1,660.61 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Intellia Therapeutics (NTLA)
| 42.5 | 19.0 | -1.6 | 9.4 | -30.2 | -40.8 | -4.3 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Intellia Therapeutics (NTLA)
| -22.9 | -61.5 | -12.6 | -70.5 | 117.4 | 270.8 | 7.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Intellia Therapeutics (NTLA)
|
12.8 | 1,803.4 | 59.5 | -400.0 | -672.2 | -57.2 | -- | 2.5 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout Intellia Therapeutics (NTLA)
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic... repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Dr. John M. Leonard M.D.
-
President, CEO & Director
Dr. John M. Leonard M.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Intellia Therapeutics (NTLA)
What is the current share price of Intellia Therapeutics Inc (NTLA) Today?
The share price of Intellia Therapeutics Inc (NTLA) is $12.82 (NASDAQ) as of 04-Sep-2026 13:36 EDT. Intellia Therapeutics Inc (NTLA) has given a return of -30.2% in the last 3 years.
What is the current PB & PE ratio of Intellia Therapeutics Inc (NTLA)?
Since, TTM earnings of Intellia Therapeutics Inc (NTLA) is negative, P/E ratio is not available.
The P/B ratio of Intellia Therapeutics Inc (NTLA) is 2.53 times as on 28-Aug-2026, a 51 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.36 |
1.45 |
2024 |
-2.29 |
1.36 |
2023 |
-5.73 |
2.63 |
2022 |
-5.98 |
2.29 |
2021 |
-33.88 |
8.46 |
What is the 52 Week High and Low of Intellia Therapeutics Inc (NTLA)?
The 52-week high and low of Intellia Therapeutics Inc (NTLA) are Rs 28.24 and Rs 7.95 as of 05-Sep-2026.
What is the market cap of Intellia Therapeutics Inc (NTLA)?
Intellia Therapeutics Inc (NTLA) has a market capitalisation of $ 1,803 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Intellia Therapeutics Inc (NTLA)?
Before investing in Intellia Therapeutics Inc (NTLA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.